Vimarsana
Biggest News Aggregation in the World

Page 48 - Billy Dunn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Billy Dunn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Billy Dunn Today - Breaking & Trending Today

FDA limits use for new Alzheimer's drug after backlash & own experts' resignations over rushed approval — RT USA News - Vimarsana News

FDA limits use for new Alzheimer's drug after backlash & own experts' resignations over rushed approval — RT USA News

Follow RT on The US Food and Drug Administration has scaled back the prescribed uses for a new Alzheimer’s drug, now limiting it to “mild” dementia cases, after several health advisers resigned in protest over a rushed approval process. Drug developer Biogen announced the new prescribing label on Thursday, noting that aducanumab – also known by its trade name, Aduhelm – should be given only to those in the early stages of Alzheimer’s. “Treatment with Aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population i...

Source: rt.com
Umstrittene Wirkung - USA prüfen Zulassung des Alzheimer-Medikaments «made in Switzerland» - Vimarsana News

Umstrittene Wirkung - USA prüfen Zulassung des Alzheimer-Medikaments «made in Switzerland»

Umstrittene Wirkung - USA prüfen Zulassung des Alzheimer-Medikaments «made in Switzerland» Publiziert Umstrittene Wirkung : USA prüfen Zulassung des Alzheimer-Medikaments «made in Switzerland» Die US-Arzneimittelbehörde FDA hat vor Wochen das Alzheimermedikament Aducanumab zugelassen, obwohl das Mittel nicht die erhoffte Wirkung zeigte. Jetzt leitet die Behörde eine Untersuchung ein – denn sie sieht ihren guten Ruf gefährdet. 1 / 3 Die US-Arzneimittelbehörde FDA hat das Medikament mit dem Wirkstoff Aducanumab im Juni 2021 zugelassen.via REUTERS as Medikament soll Patienten mit Al...

Source: 20min.ch
Two members of an FDA advisory committee quit after approval of controversial Alzheimer's drug - Vimarsana News

Two members of an FDA advisory committee quit after approval of controversial Alzheimer's drug

Two members of an FDA advisory committee quit after approval of controversial Alzheimer’s drug Laurie McGinley © Adam Glanzman/Bloomberg News The Food and Drug Administration on Monday approved the first new Alzheimer’s disease therapy in 18 years. The drug is made by Biogen, based in Cambridge, Mass. Two members of a Food and Drug Administration advisory panel resigned this week after the agency’s contentious decision to approve an Alzheimer’s drug over the objections of its outside advisers. David S. Knopman, a neurologist at the Mayo Clinic, said Wednesday i...

Source: msn.com
FDA Weighs Approval Of A Lucrative Alzheimer's Drug, But Benefits Are Iffy - Vimarsana News

FDA Weighs Approval Of A Lucrative Alzheimer's Drug, But Benefits Are Iffy

The agency is to decide byMonday whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November.

Source: usf.edu
FDA weighs approval of a lucrative Alzheimer's drug but benefits are iffy - Vimarsana News

FDA weighs approval of a lucrative Alzheimer's drug but benefits are iffy

The Food and Drug Administration's decision next week whether to approve the first treatment for Alzheimer's disease highlights a deep division over the drug's benefits as well as criticism about the integrity of the FDA approval process.